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Theileria parva is a protozoan parasite that causes East Coast fever (ECF), an
economically important disease of cattle in Africa. It is transmitted mainly by the tick
Rhipicephalus appendiculatus. Research efforts to develop a subunit vaccine based
on parasite neutralizing antibodies and cytotoxic T-lymphocytes have met with limited
success. The molecular mechanisms underlying T. parva life cycle stages in the tick
vector and bovine host are poorly understood, thus limiting progress toward an effective
and efficient control of ECF. Transcriptomics has been used to identify candidate
vaccine antigens or markers associated with virulence and disease pathology. Therefore,
characterization of gene expression throughout the parasite’s life cycle should shed
light on host–pathogen interactions in ECF and identify genes underlying differences
in parasite stages as well as potential, novel therapeutic targets. Recently, the first
gene expression profiling of T. parva was conducted for the sporoblast, sporozoite,
and schizont stages. The sporozoite is infective to cattle, whereas the schizont is the
major pathogenic form of the parasite. The schizont can differentiate into piroplasm,
which is infective to the tick vector. The present study was designed to extend the
T. parva gene expression profiling to the piroplasm stage with reference to the schizont.
Pairwise comparison revealed that 3,279 of a possible 4,084 protein coding genes
were differentially expressed, with 1,623 (49%) genes upregulated and 1,656 (51%)
downregulated in the piroplasm relative to the schizont. In addition, over 200 genes were
stage-specific. In general, there were more molecular functions, biological processes,
subcellular localizations, and pathways significantly enriched in the piroplasm than
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in the schizont. Using known antigens as benchmarks, we identified several new
potential vaccine antigens, including TP04_0076 and TP04_0640, which were highly
immunogenic in naturally T. parva-infected cattle. All the candidate vaccine antigens
identified have yet to be investigated for their capacity to induce protective immune
response against ECF.
Keywords: Theileria parva, schizont, piroplasm, transcriptome, vaccine antigens
INTRODUCTION
Cattle production constitutes a significant component of
agriculture, economy, and food security in the world, especially
in developing countries (1, 2). East Coast fever (ECF)
is a lymphoproliferative and lymphodestructive disease of
cattle caused by the hemoprotozoan Theileria parva, mainly
transmitted by the tick vector Rhipicephalus appendiculatus.
ECF kills one cow every 30 s and has a devastating impact on
pastoralists and smallholder farmers because of its rapid effect,
since animals often die within 3 to 4 weeks of infection [reviewed
by (3)]. This causes significant economic losses in 12 countries
in eastern, central, and southern Africa regions (3–6). As the
infected tick feeds on cattle, the sporozoites are inoculated in
the mammalian host at the feeding site. The sporozoites then
invade host lymphocytes and differentiate into multinucleate
bodies, called schizonts, in the cytoplasm of infected lymphocytes
after a period of 3 days. Schizonts cause the transformation of
infected host white blood cells, inducing a phenotype similar
to cancer (7, 8). Schizonts undergo merogony, and the released
merozoites invade erythrocytes and form piroplasms, which are
infective to the feeding tick that ingests parasitized erythrocytes
(9). A method of vaccination, whereby infection of cattle with
live T. parva sporozoites is done simultaneously with treatment
with long-acting oxytetracycline, was developed over 40 years
ago (10). This resulted in a live vaccine called the Muguga
Cocktail, which was developed based on a combination of
three T. parva stocks, the Muguga, Kiambu 5, and Serengeti-
transformed stocks. The Muguga Cocktail generates long-lasting
immunity in vaccinated cattle against challenge with homologous
T. parva stocks. However, ITM-vaccinated animals usually
remain carriers of the vaccine parasite strains and a source of
infections to ticks. Tremendous progress was made on ECF
research. Publication of a reference genome sequence of T. parva
has led to a more thorough characterization of the pathogen
and of the Muguga Cocktail strains (11–13). But, extensive
efforts to develop alternative, more easilymanufactured and user-
friendly, subunit vaccines have met with limited successes (3).
Therefore, it is imperative to identify more candidate vaccine
antigens. Gene expression profiling, including high-throughput
transcriptomics, has been used to identify potential diagnostic
and therapeutic targets as well as to correlate gene expression
profiles to pathologic diagnosis, clinical outcomes, or therapeutic
response (14, 15). Moreover, transcriptomics enables predictive
analysis of the structure, location, role, and functional motifs
of genes and its product. Recently, a comparative transcriptome
profiling of T. parva was done on two life cycle stages in ticks,
the sporoblast and the sporozoite (the latter is transmissible from
tick to cow upon tick feeding), and on the pathogenic schizont
stage (16). No work has yet been done on the piroplasm stage
that is transmissible from cattle to ticks. That first comparative
transcriptomic analysis revealed that the development of the
parasite from the sporozoite in the tick vector into the schizont
in the bovine host cells is accompanied by a drastic increase
of upregulated genes, though the 10 most highly expressed
genes occurred in the arthropod stages. It also identified several
genes with expression similar to known candidate vaccine
antigen genes and revealed errors in the structural annotation
of the T. parva genome. The present study was then set up
to extend the analysis of T. parva gene expression profiles
to the piroplasm stage in comparison to the schizont stage,
using the Illumina MiSeq next-generation sequencing platform.
Furthermore, data from previous (16) and current studies were
combined in our analysis for the search of new candidate
vaccine antigens.
MATERIALS AND METHODS
Sample Collection and Purification
Ethics Statements
The study reported here was carried out in strict accordance
with the recommendations in the standard operating procedures
of the ILRI IACUC and adequate consideration of the 3R’s
(replacement of animal with non-animal techniques, reduction
in the number of animals used, and refinement of techniques
and procedures that reduce pain and distress). The ILRI’s
Experimental Animal Request Form and Protocol for blood
collection was approved by the ILRI IACUC (IACUC ref
no. 2006.9, IACUC ref no. 2006.10, IACUC ref no. 2007.10,
and IACUC-RC2015-23).
T. parva schizonts proliferate in the white blood cells, whereas
piroplasms develop in the red blood cells of the host. Schizont-
infected bovine lymphocytes are easily cultured in vitro. Thus,
the schizont parasites were purified from approximately 2 ×
108 cells that were obtained from the in vitro established
T. parva (Muguga) schizont-infected bovine peripheral blood
mononuclear cell line TpM 3087 at the International Livestock
Research Institute, as previously described (16, 17). Four different
schizont purification assays were performed. The piroplasm
parasites were purified from T. parva (Muguga)–infected calf
blood when the parasitemia reached 3–70%, as previously
described (18). Three piroplasm purification experiments were
conducted. For this study, piroplasms and schizonts were T.
parva Muguga stabilate 3087, previously described by Tonui
et al. (16).
Frontiers in Veterinary Science | www.frontiersin.org 2 June 2020 | Volume 7 | Article 287
Atchou et al. Theileria Parva Developmental Stages’ Transcriptomics
RNA Extraction and cDNA Library
Preparation
Purified schizont and piroplasm parasite samples were processed
for total RNA extraction and purification using the RNAzol R© RT
isolation kit following the manufacturer’s instructions (Sigma-
Aldrich, USA). T. parva total RNA contains an abundant
ribosomal RNA thatmigrates as a strong band between the 18 and
28S host bovine rRNA on a 1.5% agarose gel electrophoresis (19).
We used this approach to verify that RNA samples contained T.
parva RNA and were not degraded before we proceeded with
subsequent analyses. Then, isolated RNA was quality-checked
and quantified using the Nanodrop R©-1000 spectrophotometer
(Nanodrop Technologies, Delaware, USA). We further checked
the integrity of the RNA using 1.2% agarose RNA gel, as described
previously (20). The poly(A)+RNA was purified from the total
TABLE 1 | Percentage of reads mapped to the reference genome transcriptome
using Kallisto and number of mapped genes.
Life cycle stage
Schizont Piroplasm
Number of sample replicates 4 3
Total trimmed reads 3,717,927 3,143,345
Mapped reads 60% 85%
Mapped genes 3,891 3,887
Combined total genes mapped 4,061
Theileria parva protein coding genesa 4,084
Using p67 (TP03_0287) as benchmark, a gene with a transcripts per kilobasemillion (TPM)
value ≤ 2.2 was considered not expressed in the stage studied.
a4,084 proteins are predicted to be encoded by the re-annotated T. parva genome (44).
RNA (16). The integrity and quantity of poly(A)+RNA were
checked as above; then, 10 ηg of RNA was used for each library.
Normalization of the schizont and piroplasm poly(A)+RNA was
done using Ambion R© ERCC Spike-In Control, as described
before (15). The TruSeq stranded total RNA Kit (Illumina
Inc., USA) was used for the library preparation according
to manufacturer instructions. The library concentration was
checked using the Qubit R© (Thermo Scientific, USA) broad
range and high sensitivity reagents, while the integrity was
checked using the Agilent Bioanalyzer 2200 TapeStation system.
For the sequencing, each library was diluted before being
pooled for sequencing to avoid over-clustering errors on
the sequencer.
Sequencing and Differential Expression
Analysis
Paired-end RNA sequencing was done at the Biosciences eastern
and central Africa-International Livestock Research Institute
(BecA-ILRI) Hub using an Illumina MiSeq sequencer following
manufacturer guidelines. The reads obtained were transferred
to the ILRI High-Performance Computing (HPC) server for
bioinformatics data analysis. The nucleotide sequence data
reported in this study are available in the NCBI database
under the accession number PRJNA604662. The quality control
of the raw reads was done using FastQC 0.11.5 (21). The
reads were cleaned, and the adapters were trimmed using
trimmomatic/0.38 and cutadap 1.16 (22, 23). An index of the
T. parva transcriptome was then built, based on the original
genome annotation (11). The trimmed reads were used for
the mapping against the built transcriptome using Kallisto
version 0.43.0 (24). The T. parva reference transcriptome
(accession no. GCF_000165365.1_ASM16536v1) was retrieved
FIGURE 1 | Clustering analysis of samples. (A) Samples’ distance matrix of replicates clustering schizont and piroplasm replicates according to the life cycle stages.
(B) Principal component analysis (PCA) of the replicates showing a variance of 99% between the schizont (blue) and piroplasm replicates (red).
Frontiers in Veterinary Science | www.frontiersin.org 3 June 2020 | Volume 7 | Article 287
Atchou et al. Theileria Parva Developmental Stages’ Transcriptomics
from NCBI GenBank. An RNA-seq pipeline was developed
using a custom Python script 3.7 for the analysis from
the quality control to the quantification. The read counts
were normalized to transcripts per kilobase million (TPM).
The count table (h5 format) was exported to R for the
gene expression analysis. In order to confirm the statistically
significant changes in gene expression and the complete data
set for different stage pairwise comparisons, gene expression
analysis was conducted. Bioconductor DEseq2 (25) based on
the negative binomial distribution packages was used to identify
differentially expressed genes at the different parasite stages.
Genes were regarded to be differentially expressed when the q
value cutoff (FDR adjusted p-value using Benjamini–Hochberg
model) was lower than 0.05. The differentially expressed genes
were plotted using the Bioconductor EnhancedVolcano package
in R (26).
The quality control was also performed on the unmapped
reads. They were de novo assembled to form contigs using
Trinity v2.6.6 (27). The transcripts were then blasted
against the non-redundant (nr) GenBank database. The hit
contigs from Trinity were mapped back to the T. parva
reference genome.
Functional Enrichment of the Differentially
Expressed Genes and Vaccine Candidate
Antigen Prediction
Functional annotation of the significant differentially expressed
genes between the infection stages was performed using
the Database for Annotation, Visualization and Integrated
Discovery (DAVID Bioinformatics Resources 6.8, NIAID/NIH).
Gene Ontology (GO) term enrichment was analyzed for
functional classification of selected up- and downregulated
genes in each of the two parasite stages. In silico search
of the N-terminal signal peptide (SP), trans-membrane
domain (TMD), nuclear localization signal (NLS), C-terminal
glycosylphosphatidylinositol (GPI) anchor signal, prediction
of protein function, and non-classical protein secretion were
analyzed using bioinformatics tools SignalP 4.0 (28), Protter
server (29), PredictProtein (30), PredGP (31), and SecretomeP
2.0 server (32), respectively, as described previously (16, 33).
Genes having similar expression patterns to known T. parva
vaccine antigens were also identified using PAM unsupervised
clustering algorithm in R with k = 50 (34, 35). Antibody epitope
residue scores (B-cell epitopes) were predicted using BepiPred
Linear Epitope Prediction 2.0 (http://tools.iedb.org/bcell) for
FIGURE 2 | Differential gene expression between schizont and piroplasm stages using Bioconductor EnhancedVolcano package in R. The graph shows the
distribution of the upregulated genes between schizont (blue dots) and piroplasm (red dots) stages with the exception of the non-differentially expressed or unchanged
genes (gray dots). Each dot in the EnhancedVolcano diagram represents one differentially expressed gene. The x-axis represents the Log2 fold change, and the y-axis
shows the –Log10 adjusted P-value.
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genes encoding proteins predicted to be localized on the surface
of the parasite (having a predicted TMD or GPI anchor). The
prediction tools are available on the Immune Epitope Database
Analysis Resource (IEDB) (http://tools.iedb.org/). The Kyoto
Encyclopedia of Genes and Genomes (KEGG) database (https://
www.genome.jp/kegg/) (36) was used to predict the metabolic
pathway of the proteins, whereas MDLocProtein (37), YLoc (38),
and WOLF PSORT II (39) were used to identify the subcellular
localization of the proteins having a predicted domain.
Preliminarily Validation of Candidate
Vaccine Antigens Using an Enzyme-Linked
Immunosorbent Assay
Selected sera from naturally infected and ECF-positive cattle,
identified using a polymorphic immunodominant molecule
(PIM)–based indirect enzyme-linked immunosorbent assay
(ELISA) test (40, 41), were used to assess the antigenicity of
potential vaccine antigens and predicted epitopes. The antigen
open reading frame was PCR amplified, cloned into a pET-32a+
plasmid vector, then over-expressed in Escherichia coli BL21,
and affinity-purified as previously described (42). The BepiPred-
predicted peptide epitopes were synthesized and lyophilized
(Pepscan, Netherlands). Peptides were dissolved in 1ml of 50%
(v/v) analytical grade acetonitrile/water (Applied Biosystems) to
a final concentration of 2 mg/ml (2 µg/µl). The ELISA was
performed as previously described (41) with a serum dilution of
1:5. Each serum was tested three times. The plates were read at
405 nm with the Immunoskan ELISA reader using the program
EDI. Data analysis was performed using the ELISA program
integrated into the ELISA reader and the results were presented
as percent positivity (PP). Predetermined bovine positive (PP
≥ 80) and negative control (PP ≤ 10) sera and antigen (lysate
from culture of E. coli BL21 containing pET-32a+ plasmid vector
expressing thioredoxin fusion tag) were included in each ELISA
test plate. Optical density (OD) readings from the reference
positive control sera were used to compute the PP for the test
sera. PP values of 20 and above were considered positive for
T. parva as previously described (41, 43). Selected ECF-positive
sera were collected in 2017 at Gitega and Gankuzo, Burundi,
and stored at BecA-ILRI Hub (Courtesy of Dr Lionel Nyabongo,
ISABU, Burundi).
RESULTS
Kallisto Read Mapping to the Reference
Transcriptome
Previously, we showed that Kallisto generatesmoremapped reads
than TopHat2 (16). Therefore, Kallisto was used to map schizont
and piroplasm paired-end reads to the T. parva reference
FIGURE 3 | Gene expression profile in the schizont and piroplasm life cycle stages. (A) Heatmap of all the differentially expressed genes. (B) Heatmap of the top 20
most variable genes between schizont replicates and piroplasm replicates. The genes were clustered into two groups: from genes XM_760801.1 to XM_757627.1
where genes were upregulated in piroplasm and downregulated in schizont, and from XM_757604.1 to XM_758863.1 where genes where upregulated in schizont and
downregulated in piroplasm. The genes were clustered by hierarchical clustering within each horizontal partition and replicates for the infection stages within each
vertical partition by similarity. Color red denotes high expression, yellow denotes stable expression, and blue denotes low expression. The colors are scaled per row.
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transcriptome and to quantify transcript abundance in each
sample replicate (Supplementary Data File 1). Out of 3,717,927
schizont trimmed reads, the average percentage of mapped reads
for the four technical replicates was 60%, while out of 3,143,345
piroplasm trimmed reads, the average percentage of mapped
reads for the three technical replicates was 85% (Table 1). The
schizont reads mapped to transcripts of 3,891 genes, whereas
reads from the piroplasmmapped to transcripts of 3,887 genes. In
total, 4,061 different protein coding genes were identified by the
combined schizont and piroplasm reads out of a possible 4,084
protein coding genes predicted by the recent re-annotation of the
T. parva genome (44).
Kallisto was used to normalize the counts in TPM, to avoid
biases induced by external factors. The normalization is essential
to ensure that the expression distributions of each sample are
similar across the entire experiment to account for differences
in gene length and in sequencing depth across replicates. The
gene expression data were displayed using clustering methods
that group genes and sample replicates together based on
the expression pattern similarities. Samples’ distance matrix
of replicates (Figure 1A) and principal component analysis
(PCA) analyses (Figure 1B) clustered the replicates according
to the life cycle stages and the divergence between each pair
of samples (Figure 1). No significant difference was observed
among replicates of the same life cycle stage. The four schizont
replicates clustered together, while the three piroplasm replicates
also clustered together.
Gene Expression in the Schizont and
Piroplasm Stages of T. parva
We used the sporozoite antigen p67 (TP03_0287), which is
not expressed in the schizont stage, as a benchmark to set the
minimum TPM expression threshold above 2.2 (TPM > 2.2).
Therefore, a gene with a TPM value ≤ 2.2 was considered not
expressed in the life cycle stages studied. Pairwise comparison
was performed in the piroplasm relative to the schizont stage.
Thus, 3,279 genes were differentially expressed between the two
stages, with roughly half of them being significantly upregulated
in each stage (Figure 2). We found that 1,624 (51%) genes were
upregulated, whereas 1,656 (49%) were downregulated in the
piroplasm with reference to the schizont (Figure 2).
A heatmap of the differentially expressed genes was also
generated with clustering methods that group genes and
replicates by gene expression profile, showing once again that
replicates from the same life cycle stage are most similar to each
other (Figure 3A). A heatmap was also performed to identify
the profile of the top 20 most variable genes across the two
stages studied, which showed that 8 were upregulated in the
schizont stage (Figure 3). These were: XM_757611.1 (TP05_
0035), XM_757608.1 (TP05_0032), XM_760371.1 (TP02_0896),
XM_757595.1 (TP05_0019), XM_757604.1 (TP05_0028), XM_
757605.1 (TP05_0029), XM_757596.1 (TP05_0020), and XM_
758863.1 (TP04_0321). Some of them code for hypothetical
proteins with SP and/or TMDs such as TP05_0020, TP05_0035,
and TP05_0032. The remaining 12 most differentially expressed
TABLE 2 | Top 20 highest expressed stage-specific genes.
GenBank acc. no. Gene ID TPM values Domains Product name
Schizont Piroplasm
XM_758142.1 TP03_0217 0 3,318 SP Hypothetical protein
XM_757627.1 TP03_0905 0 924 3 TMD Hypothetical protein
XM_758244.1 TP03_0319 0 463 (-) Hypothetical protein
XM_757628.1 TP03_0906 0 156 5 TMD Hypothetical protein
XM_760967.1 TP01_0540 0 130 (-) Hypothetical protein
XM_757613.1 TP05_0037 2,060 0 2 TMD Hypothetical protein
XM_757596.1 TP05_0020 1,714 0 3 TMD Hypothetical protein
XM_757611.1 TP05_0035 1,496 0 TMD Hypothetical protein
XM_757616.1 TP05_0040 1,271 0 2 TMD Hypothetical protein
XM_757610.1 TP05_0034 992 0 2 TMD Hypothetical protein
XM_757608.1 TP05_0032 977 0 1 TMD Hypothetical protein
XM_757584.1 TP05_0008 689 0 (-) Ribosomal protein L14, putative
XM_757605.1 TP05_0029 586 0 (-) DNA-directed RNA polymerase beta’ chain
XM_757598.1 TP05_0022 567 0 1 TMD Hypothetical protein
XM_757618.1 TP05_0042 433 0 (-) DNA-directed RNA polymerase subunit beta
XM_757599.1 TP05_0023 420 0 (-) ClpC molecular chaperone, putative
XM_757604.1 TP05_0028 418 0 (-) DNA-directed RNA polymerase subunit beta (PEP)
XM_757591.1 TP05_0015 409 0 (-) 50S ribosomal protein L36, apicoplast
XM_760366.1 TP02_0891 320 0 (-) Hypothetical protein
XM_757617.1 TP05_0041 277 0 1 TMD Hypothetical protein
Expression threshold= TPM >2.2. (Genes with a TPM ≥ 2.2 were considered as not expressed, and their TPM values were set to 0). SP, signal peptide; TMD, trans-membrane domain;
(-), none.
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genes were downregulated in the schizont and highly expressed
in piroplasm [XM_760801.1 (TP01_0367), XM_759800.1 (TP02_
0327), XM_758327.1 (TP03_0400), XM_758142.1 (TP03_0217),
XM_758455.1 (TP03_0520), XM_758206.1 (TP03_0281), XM_
760234.1 (TP02_0760), XM_757627.1 (TP03_0905), XM_
759970.1 (TP02_0497), XM_758208.1 (TP03_0283), XM_
760090.1 (TP02_0617), and XM_758290.1 (TP03_0363)].
Genes TP03_0281 and TP03_0283 encode cysteine proteases
containing a TMD. In contrast, genes TP01_0367, TP02_0327,
TP02_0617, TP03_0008, TP03_0217, TP03_0363, TP03_0400,
TP03_0520, and TP03_0905 all code for hypothetical proteins
TABLE 3 | Top 20 highest expressed genes.
GenBank acc. Gene_ID TPM values Name Domains
Schizont Piroplasm
XM_758863.1 TP04_0321 69,380 145 Histone H3 (-)
XM_758864.1 TP04_0322 55,504 1,307 Histone H2A (-)
XM_758946.1 TP04_0404 51,621 1,830 Histone
H2B-III
(-)
XM_759218.1 TP04_0675 48,611 831 Histone H4 (-)
XM_759220.1 TP04_0677 48,611 831 Histone H4 (-)
XM_760801.1 TP01_0367 13 39,381 Hypothetical
protein
SP, GPI
XM_758723.1 TP04_0181 255 29,488 Hypothetical
protein
(-)
XM_758206.1 TP03_0281 23 22,581 Cysteine
proteinase
1 TMD
XM_759800.1 TP02_0327 9 22,413 Hypothetical
protein
SP
XM_759624.1 TP02_0148 2,748 15,381 Heat shock
protein 70
(-)
XM_760882.1 TP01_1228 15,366 13,213 Hypothetical
protein
(-)
XM_758327.1 TP03_0400 4 8,567 Hypothetical
protein
SP, GPI
XM_758444.1 TP03_0509 1,933 7,550 Hypothetical
protein
(-)
XM_761484.1 TP01_1056 413 6,930 32 kDa
surface
antigen
SP, 1 TMD,
GPI
XM_759970.1 TP02_0497 42 6,586 AP2/ERF
domain
(-)
XM_760881.1 TP01_1233 6,395 704 Hypothetical
protein
(-)
XM_758455.1 TP03_0520 4 5,268 Hypothetical
protein
(-)
XM_758208.1 TP03_0283 25 3,898 Cysteine
proteinase
1 TMD
XM_759756.1 TP02_0283 1,010 3,792 60S
ribosomal
protein L39
(-)
XM_757976.1 TP03_0050 568 3,594 60S
ribosomal
protein L24
(-)
GPI, glycosylphosphatidylinositol anchor; (-), none.
with a predicted SP, except for TP03_0905, which contains
one TMD.
Stage-specific genes were also identified and are presented in
Supplementary Data File 2. The top 20 most highly expressed
stage-specific genes are presented in Table 2. These genes will be
further investigated by qRT-PCR.
The Top 5 of the 20 Most Highly Expressed
Genes Occurred in the Schizont Stage
The level of expression of the 20 most highly expressed
genes identified in this study varied from 3,594 TPM for
TP03_0050 (in the piroplasm) to 69,380 TPM for TP04_0321
(in the schizont) (Table 3). Only six of them encode for
proteins with specific domains, including four (TP01_0367,
TP02_0327, TP03_0400, and TP01_1056) containing an N-
terminal SP. The five most highly expressed genes occurred in
the schizont stage, namely TP04_0321, TP04_0322, TP04_0404,
TP04_0675, and TP04_0677, all of which encode histone
proteins. However, most of the 20 most highly expressed genes
were preferentially expressed in the piroplasm stage rather
than in the schizont. TP04_0675 and TP04_0677 had the same
TPM counts (Table 3). A BLAST search revealed that the
two genes code for the same protein, a 103-amino-acid-long
putative histone H4.
Functional Annotation of the Upregulated
Genes in the Piroplasm Stage
GO of differentially expressed genes for the two stages in
the bovine white and red blood cells was classified according
to three major categories on DAVID: molecular functions,
biological processes, and cellular component. There were 2,116
functional categories assigned to over-expressed genes in the
piroplasm relative to the schizont. The GO categories associated
with upregulated genes in the piroplasm stage referred to
711 molecular functions, 1,194 biological processes, and 211
subcellular localizations (Figures 4A–C).
There were 711 molecular functional categories assigned to
genes upregulated in the piroplasm relative to the schizont.
The molecular function categories that were most broadly
enriched included nucleic acid and ion binding, cysteine
peptidase, protein kinase, and translation initiation factor activity
(Figure 4A), which included ATP binding, catalytic activity,
purine ribonucleoside triphosphate binding, and carbohydrate
derivative binding.
Biological process categories assigned to genes upregulated in
the piroplasm (1,194) included genes involved in the nitrogen
metabolic process, cellular biosynthesis process, and gene
expression. In contrast, the biological processes such as single
organism process, response to stress, and amino acid activation
were significantly enriched in the schizont (Figure 4B). Cellular
component categories assigned to genes upregulated in the
piroplasm (211) were most broadly enriched in the intracellular
ribonucleoprotein complex and ribosome (Figure 4C).
To better understand the potential function of the
differentially expressed genes, pathway analysis was performed. A
difference was observed between up- and downregulated genes,
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FIGURE 4 | Gene Ontology (GO) functional classification for differentially expressed genes in the two developmental stages studied. (A) Molecular function category.
(B) Biological process category. (C) Subcellular localization. (D) Kyoto Encyclopedia of Genes and Genomes (KEGG) database of the categorized genes
downregulated in schizont and upregulated piroplasm. Genes without ontology information are not included. The proportion number of each GO and KEGG term of
schizont and piroplasm is, respectively, presented in the parentheses in front of the GO and KEGG terms. Red color indicates most enriched (2), and blue, no
enrichment (0). The expression level is color coded: red for over-expressed, white for unchanged. (E) Pathway map of SNARE interactions in vesicular transport. This
pathway is annotated with most of the hypothetical proteins among all the referred pathways. The arrows in the pathway indicate the molecular interaction or reaction.
The green boxes are hyperlinked to identified genes (encoded proteins) involved in the reaction, and the green box with a red star is hyperlinked to the hypothetical
proteins involved in the pathway. Schi represents schizont stage, and Piro, piroplasm.
in that 106 upregulated genes and over thrice as many (366)
downregulated genes were associated to pathways in the KEGG
database. The enriched pathways are shown in Figure 4D. The
top signaling pathways annotated, to which genes upregulated in
the piroplasm stage belong, included ribosome and spliceosome.
To contribute to the knowledge of parasite genes potentially
involved in vesicular transport signal pathways, we identified
in the differentially expressed genes SNARE (soluble N-
ethylmaleimide–sensitive factor attachment protein receptor)
protein homologs using KEGG Mapper (Figure 4E); targets
identified are primarily genes encoding hypothetical proteins
and mostly downregulated in the schizont. The list of genes
associated to each GO term and KEGG term is presented in
Supplementary Data File 3.
Genes With Functional Domains and
Expression Patterns Similar to Known T.
parva Antigen Genes
To identify genes that have a similar expression pattern to
known vaccine antigen-coding genes, gene expression profiles
and functional domains and motifs of these known antigens were
first generated (Table 4). The analysis was expanded to include
data previously reported for two tick vector stages (sporoblast
and sporozoite) as well as the schizont (16). These known
antigens are differentially expressed across the infection stages.
However, except for the p67, which was not expressed in the
piroplasm stage (0 TPM), all the other known antigens were
differentially expressed across all the stages studied.
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TABLE 4 | Expression profile of known T. parva antigens.
Locus tag ID Antigen name TPM values Product name Domains
Sporoblast* Sporozoite* Schizont* Schizont Piroplasm
TP03_0849 Tp1 111 990 155 320 201 CD8+ T-cell target antigen SP
TP01_0056 Tp2 309 1,427 625 533 39 CD8+ T-cell target antigen SP
TP01_0868 Tp3 280 61 145 25 176 CD8+ T-cell target antigen SP
TP03_0210 Tp4 369 431 242 309 199 T-complex protein 1 subunit eta (-)
TP02_0767 Tp5 702 503 292 249 175 Translation initiation factor eIF-1A (-)
TP01_0188 Tp6 475 261 275 248 151 Prohibitin SP
TP02_0244 Tp7 2,363 2,324 803 2,034 1,067 Heat shock protein 90 (-)
TP02_0140 Tp8 3,146 1,658 4,315 3,044 2,740 Cysteine proteinase SP
TP02_0895 Tp9 273 6,384 1,497 708 5 CD8+ T-cell target antigen SP
TP04_0772 Tp10 954 515 1,090 300 290 Coronin (-)
TP03_0287 p67 17,464 840 21 3 0 Hypothetical protein SP, 1 TMD
TP04_0051 PIM 322 3,361 961 2,661 905 Polymorphic immunodominant molecule SP, 3 TMD
TP01_0939 gp34 24 261 113 101 113 Hypothetical protein SP, 1 TMD
TP04_0437 p104 15 11,151 539 395 39 104 kDa microneme/rhoptry antigen SP, GPI
TP03_0445 PCNA 1,225 102 271 337 102 Proliferating cell nuclear antigen (-)
TP02_0600 PCNA 710 49 420 314 181 Proliferating cell nuclear antigen NLS
*Data from Tonui et al. (16).
The p67 TPM value was considered as background and was subtracted from the expression value of each antigen. GPI, GPI anchor; NLS, nuclear localization signal; PIM, polymorphic
immunodominant molecule; (-), none.
Unsupervised clustering using the PAM clustering algorithm
in R was performed to identify genes that cluster with, and thus
have a similar expression pattern to, known antigens (Figure 5;
Supplementary Data File 4 Sheet 1). Several genes had a similar
expression pattern to known antigens, including 10 or more
that were similar to Tp1, Tp2 and Tp3, Tp4, Tp5, Tp6, Tp10,
gp34, and PCNA 1 (TP02_0600); 6 that were similar to Tp9;
5 similar to both PCNA 2 (TP03_0445) and Tp7; 3 similar to
p104; and 1 gene similar to PIM. However, we did not find
any gene with similar expression patterns to Tp8 and p67.
Those with an SP, TMD, and/or GPI anchor are shown in
Supplementary Data File 4 Sheet 2.
Vaccination against ECF using the major T. parva sporozoite
surface protein p67 can induce antibody-based immune
protection in up to 50% of vaccinated animals (3, 45). To support
the identification of additional candidate vaccine antigens able to
induce protective antibodies like p67, T. parva genes encoding
proteins containing TMDs or GPI anchors were analyzed in
silico using the epitope prediction algorithm BepiPred Linear
Epitope Prediction 2.0 for the presence of epitopes that are
targets of antibodies (Supplementary Data File 5). Using p67
antigen as the benchmark, the top 20 proteins among the
candidate vaccine proteins predicted to be localized in the
parasite plasma membrane (Supplementary Data File 5) were
ranked for their antigenic propensity and/or probability to
contain antibody epitopes based on the score of the predicted
peptide epitopes, which varied between 0.749 (XP_763541.1) and
0.566 (XP_764275.1), compared to the p67 antigen score of 0.658
(Table 5) or PIM antigen of 0.650.
Unmapped Reads Mainly Originate From
the Bovine Genome
De novo assembly of unmapped reads from schizont samples, i.e.,
40% of total trimmed reads (Table 1), using Trinity, generated
10,823 contigs. BLAST searches for sequence similarity were
performed using the new contigs. Most of the hits mapped
to mammalian genomes in the family Bovidae, including Bos
mutus, Bos taurus, Bos indicus, and Bison bison (Figure 6A).
By assuming that all these genes are more likely orthologs
to the bovine host genes, then in total, 71% of the schizont
stage unmapped reads hit the bovine genome. The second
large hit was the T. parva genome to which 23% of the total
blast hits mapped. Other blast hits included bacteria (E. coli)
and synthetic constructs, which may be plasmids from the E.
coli above. Trinity de novo assembly of piroplasm unmapped
reads produced 2,064 contigs, of which 90% mapped to bovine
and about 5% to Theileria genomes. The contigs mapped
to the T. parva genome identified 32 genes (Figure 6B). It
is likely that the structure of those genes was not correctly
identified in the original annotation and thus was incomplete
or had gaps in the reference transcriptome used for the
mapping, as we demonstrated previously (16). These have
now been re-annotated accordingly (44). Most of the 32
genes identified by both schizont and piroplasm contigs of
unmapped reads were hypothetical proteins. Known genes coded
for ABC transporters, ribosomal proteins, heat shock proteins
(including heat shock protein 90, known as Tp7 or TP02_0244),
or 23 kDa piroplasm surface protein TP02_0551, among
others (Figure 6B).
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FIGURE 5 | Genes with expression profiles similar to known Theileria parva antigens’ genes. Sporoblast, sporozoite, and schizont_a are transcriptome data collected
from our previous work (16), whereas schizont_b and piroplasm are transcriptome data generated from this study. Each line in a unique color represents a specific
gene with its GenBank accession number. Each plot represents the profiling of genes (GenBank accession number listed) having a similar expression profile to the
known antigen (top of the plot).
ELISA Validation of Potential Vaccine
Antigens
We chose two candidate vaccine antigens among the predicted
parasite plasma membrane proteins (Table 5) to evaluate their
immunogenicity potential. TP04_0076 and TP04_0640 genes
were selected because they may encode plasma membrane
proteins, have strong predicted antibody epitope residue scores
[0.677 and 0.566, respectively (Table 5)], and encode very
small proteins (only 96 and 114 amino acids, respectively)
that may therefore be easy to express in E. coli and purify.
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TABLE 5 | Top 20 T. parva surface proteins with high antibody epitope prediction values and with expression similar to known antigen.
Gene ID Protein ID SP SZ Sca Scb PRM ESA DM Name SLP NE HPRS
TP03_0513 XP_763541.1 150 800 335 296 199 Tp1 5 TMD HP PM 7 0.749
TP02_0615 XP_765181.1 345 174 14 9 31 Tp3 7 TMD RING-type
domain-containing protein
PM 20 0.738
TP03_0544 XP_763572.1 32 1,568 360 203 98 Tp2 10 TMD HP PM 6 0.717
TP01_1200 XP_766721.1 295 22 97 49 13 Tp3 7 TMD Phosphodiesterase PM 11 0.711
TP02_0232 XP_764798.1 503 1,387 266 274 19 Tp2 11 TMD HP PM 10 0.709
TP01_0509 XP_766029.1 104 339 134 163 99 gp34 SP, 1 TMD HP ES 13 0.709
TP03_0168 XP_763186.1 91 437 639 358 108 Tp4 SP, 1 TMD HP PM 88 0.703
TP03_0165 XP_763183.1 19 366 123 131 3 gp34 9 TMD ABC transporter NS 34 0.702
TP01_1013 XP_766534.1 146 310 96 88 165 gp34 SP, 7 TMD MtN3/RAG1IP protein PM 9 0.700
TP04_0448 XP_764083.1 276 22 28 25 76 Tp3 8 TMD HP PM 21 0.699
TP01_0506 XP_766026.1 145 556 242 195 162 Tp4 SP, 1 TMD GOLD domain-containing
protein
ES 7 0.679
TP04_0076 XP_763711.1 4,952 608 727 907 1,097 Tp7 2 TMD HP PM 2 0.677
TP02_0183 XP_764747.1 62 288 151 112 97 gp34 9 TMD HP PM 21 0.674
TP04_0803 XP_764440.1 98 370 318 236 205 Tp4 8 TMD TPT domain-containing
protein
PR 11 0.659
TP03_0287 XP_763305.1 17,465 840 21 3 2 p67 SP, 1 TMD HP PM-ES 18 0.658
TP03_0175 XP_763193.1 1,063 42 21 90 147 PCNA SP, TMD HP ES 18 0.658
TP04_0907 XP_764544.1 3 336 102 91 6 gp34 18 TMD HP PR 23 0.652
TP03_0895 XP_763368.1 61 308 432 256 121 Tp4 12 TMD Folate/biopterin transporter PM 17 0.650
TP03_0455 XP_763475.1 238 17 61 64 119 Tp3 SP, 6 TMD HP PM 10 0.645
TP04_0640 XP_764275.1 136 8,957 671 794 202 p104 1 TMD HP PM 2 0.566
*p67 antigen is used as reference for the prediction value. SP, sporoblast; SZ, sporozoite; SCa, schizont a; Scb, schizont b; PRM, piroplasm; DM, domain; ES, extracellular localization;
ESA, expression similar to known antigen; HP, hypothetical protein; HPRS, highest epitope predicted residue scores; NE, number of predicted epitopes; PM, plasma membrane; NS,
nucleus; PR, peroxisome; SLP, subcellular localization prediction.
Furthermore, TP04_0076 (XM_758618.1) has an expression
profile similar to Tp7, and that of TP04_0640 (XM_759182.1)
is similar to the p104 antigen gene (Figure 5). TP04_0640
was proposed as a potential target for the development of
anti-Theileria drugs (16). Recombinant protein was generated
only for TP04_0076. The TP04_0076 ORF was cloned into
pET-32a+, over-expressed as a recombinant fusion protein in
the E. coli system, and affinity-purified. The fusion protein
was termed TP04_0076F (Figure 7). We procured synthetic
peptides corresponding to the following predicted antibody-
targeted epitopes: TP04_0076ep1 (19-mer: MADLTKRKPHSTS
FVDLTR) in TP04_0076, and TP04_0640ep1 (19-mer: PDRF
FNKIGIIYYPSKHWS) and TP04_0640ep2 (30-mer: ERTKHPR
LDSFDSMIDEYSTVENDGGIMYF), both in TP04_0640. As
previously described (16), TpMuguga_04g00640 encodes a
protein that is 50 amino acids longer than that of TP04_0640,
the corresponding locus predicted in the original 2005 genome
annotation, as it now encodes a protein of 114 amino
acid residues.
The antigenicity of both the purified recombinant fusion
protein and synthetic peptides was tested using cattle sera that
exhibited a strong positive response in a PIM-based ELISA. In
total, and since we lacked sufficient volume to test all 34 strong
positive sera against all epitopes, TP04_0076F was tested with
34 sera, and TP04_0076ep2, TP04_0640ep1, and TP04_0640ep2,
with 20 sera (Figure 8). Three negative control sera were included
(Supplementary Data File 6).
All the 34 infection sera analyzed were positive with the
recombinant fusion protein TP04_0076F, with PP ranging from
20 to 140 PP (cutoff value: PP ≥ 20). Equally, all the sera tested
with the synthetic peptide epitope TP04_0640ep2 produced a
positive antibody reaction. Six sera showed higher levels of
antibody reaction to the recombinant protein TP04_0076F and
derived epitope TP04_0076ep1 than the positive control PIM
which is being used as a diagnostic antigen (Figures 8A,B).
In contrast, all the sera tested with the TP04_0640ep2 epitope
gave positive antibody reactions but at lower levels than PIM
(Figure 8D). Out of 20 sera tested with TP04_0640ep1, 16 (80%)
were positive (Figure 8C). The OD reading of each antigen and
the positive and negative control sera and antigen are presented
in Supplementary Data File 6. All the antigens tested produced
a very weak or no reaction to the negative control sera. The
presence of antibodies in the sera was a preliminary indication
of the antigenicity of these potential antigens.
DISCUSSION
This research was undertaken in order to enhance our knowledge
and understanding of gene expression across T. parva life cycle
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FIGURE 6 | Analysis of unmapped reads. (A) Count of BLAST hits to unmapped reads. (B) Counts of BLAST hits of unmapped reads to T. parva genome.
FIGURE 7 | Amino acid sequences of the recombinant fusion protein TP04_0076F. The fusion protein contains 260 aa (single letter peptide) with the vector portion
underlined and the 6x His tag used for affinity purification shadowed. The TP04_0076 portion is bolded, and the methionine (M) start codon was not included in the
fusion protein.
stages, specifically from schizont to piroplasm forms, and in
this way improve predictive analysis of their structure, location,
role, and function that may lead to the identification of novel
therapeutic targets.
A comparison of the transcriptome data from next-generation
sequencing of the two stages pointed to 3,279 differentially
expressed genes between the schizont and the piroplasm stage,
out of 4,061 protein coding genes with our expression data, with
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FIGURE 8 | Enzyme-linked immunosorbent assay (ELISA) evaluation of the antigenicity of (A) TP04_0076 gene product (recombinant protein TP04_0076F) and
predicted antibody target epitopes of TP04_0640 and TP04_0076 gene products (synthetic peptides (B) TP04_0076ep2, (C) TP04_0640ep1, and (D)
TP04_0640ep2). A panel of 34 predetermined bovine positive controls with strong percent positivity (PP ≥ 80) to PIM antigen (red line) were included in the analysis.
The PP results of each of the four recombinant proteins and synthetic peptides tested (blue line) are shown in separated panels. The green line represents the cutoff,
and an assay with a PP ≥ 20 (PP ≥ 20) is considered positive.
roughly half of them being significantly upregulated in each of
these two stages that take place, respectively, in the host white
blood cells and red blood cells. To capture the whole expression
profile of the parasite, we summarize inTable 6 the transcriptome
data sets of the different life cycle stages, by combining our
current data with a similar study previously conducted on the
sporoblast, sporozoite, and schizont stages (16). Shaw et al.
(42) have proposed that T. parva uses repeatedly a single set
of genes (termed “cassettes”) throughout its life cycle with the
replacement of only a few each time to allow for small differences
in reproduction (46). These genes are regulated by a limited
number of promoter motifs (47). Consistent with this scenario,
the results presented here and in our previous work show that
almost all genes are expressed in most stages, albeit across a
wide range of expression levels, with only about 200 being stage-
specific. It worth noting that, as the parasite developed from
sporoblast to sporozoite and then schizont stages, the number
of differentially expressed genes increased (16) and then slightly
decreased from the schizont to the piroplasm stages (this study).
The top five most highly expressed genes are over-expressed
in the schizont stage and encode histone protein family members
(Table 3). However, Tonui et al. (16) observed that the level
of expression of these histone genes was even much higher in
stages in the arthropod vector (sporoblast and sporozoite) than
in the schizont stage. Our results are also consistent with those
obtained in a T. parva proteome characterization study, where
histone protein family members were highly expressed (48).
It was reported that histone modification operates in synteny
with transcription factors and is mostly activated during the
replicative schizont stage (49, 50). Experiments using apicidin,
a histone deacetylase inhibitor, were shown to alter parasite
differentiation status, leading to the conclusion that epigenetic
control plays a key role in apicomplexan differentiation steps
(51). This observation is consistent with our results, which
show histone-encoding genes to be among the most highly
differentially expressed genes across the parasite life cycle studied.
Genes encoding known proteins such as cysteine proteinase
(TP03_0281) and heat shock protein 70 (TP02_0148) were also
found very highly expressed in the piroplasm, with, respectively,
22,581 and 15,381 TPM. TP03_0281 protein contains a TMD
and secretion activity. This is not unexpected, as these genes
encode enzymes that degrade protein and could be required for
morphological events or degradation of host cell proteins (52).
All known antigens (45, 53, 54) were expressed at each
developmental stage (Table 4), except for p67; this protein is
known to be a sporozoite surface protein and only present in the
sporozoite infection stage, although the gene was shown recently
to be highly expressed by the sporoblast stage (16). We also
observed that the expression of known antigens is not conserved
across the stages (Figure 5). We included in our analysis the
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TABLE 6 | Number of T. parva genes differentially expressed in the tick vector and
bovine host.
Life cycle stages
Gene status Sporoblasta Sporozoitea Schizonta Piroplasmb
(compared to
schizontb)
Downregulated 1,136 1,517 4 1,623
Upregulated 1,332 1,626 3,862 1,656
Total
differentially
expressed
2,468 3,143 3,866 3,279
Total genes
mapped
3,924 4,061
aData from Tonui et al., (16). b This study.
two mammalian stages (schizont and piroplasm) of the parasite
and the two vector stages (sporoblast and sporozoite) from our
previous work (16), to identify potential new vaccine antigens
as well as novel therapeutic targets among those with a similar
expression pattern to T. parva known antigens. Unsupervised
clustering was used to cluster the expressed genes in the parasite
life stages. This method has been used in related studies on gene
expression data to identify markers associated with virulence,
disease pathology that could be used for reverse vaccinology and
therapeutic target identification (14, 15, 55). Many co-expressed
genes are often co-regulated and have similar expression profiles.
Thus, genes with similar expression to the known antigen genes
could aid in identifying novel protein targets to improve control
strategies against ECF. Since T. parva is an intracellular parasite,
we prioritized identification genes coding for proteins that are
secreted by the parasite (containing an SP) or that are located on
the surface of the parasite, i.e., containing TMDs or a predicted
GPI anchor, and those that contain predicted antibody target
epitopes (Table 5) (15, 56). Combining these characteristics and
using the p67 and the diagnostic antigen PIM as benchmarks,
we identified a number of potential candidate vaccine antigens
[some of which were also identified in a previous study (16)]
that are likely to be target of protective immune responses
during ECF. In that regard, the ELISA results for TP04_0076
and TP04_0640 showed that these proteins induced antibody
reactions in naturally T. parva-infected cattle. Particularly,
TP04_0076 antigen could induce antibody reactions in some
infected cattle at greater levels than the benchmark diagnostic
antigen PIM. This is consistent with a previous report that ITM-
immunized animals recognized recombinant TP04_0076 (57).
A BLASTN revealed a homology to the conserved Theileria
annulata gene XM_947675.1 (86.12% sequence identity, E-value
of 8e−55), to the immunodominant Plasmodium falciparum
UB05 gene (KF875450.1; 100% sequence identity, E-value
of 9e−149), and to the conserved Theileria orientalis strain
Shintoku gene XM_009694457.1 (80% sequence identity, E-value
of 4e−04). It is reported that the TP04_0076 antigen was better
at detecting antigen-specific antibodies in the plasma of human
subjects with malaria compared to Plasmodium homolog UB05
when tested by ELISA (57). TP04_0640 was also found similar
to the meiotic upregulated gene MUG84 of yeast endoplasmic
reticulum membrane encoding for phosphatidylinositol N-
acetylglucosaminyltransferase subunit P (PIG-P) (16). This
protein is an enzyme involved in GPI anchor biosynthesis.
However, further investigation is necessary to determine if these
antigens can be protective against ECF and to evaluate if they
can prevent sporozoite infection of cattle or block piroplasm
transmission to ticks.
This study expanded our knowledge of T. parva genes
involved in biological pathways, as this information is limited
compared to other apicomplexan parasites (58, 59).We identified
transcription factors that were upregulated in the piroplasm
including genes involved in nucleic acid and ion binding.
A number of hypothetical proteins were also identified as
potential SNAREs involved in intracellular vesicular transport.
Several of these potential SNARE proteins identified have a
TMD and at least a 60-amino-acid-long coiled-coil region as
described previously (60). The SNARE interactions shown in
Figure 4E involved the plasma membrane, the Golgi body, and
the endoplasmic reticulum–related transport pathways. These
genes could be investigated for their specific interaction and roles
in the development of T. parva.
This study shed more light upon gene expression variation
as the apicomplexan protozoa T. parva develops through its
life cycle stages in the tick vector and bovine host, resulting in
the establishment of ECF. In addition, bioinformatic analysis
of transcriptomics data identified potential candidate vaccine
antigens yet to be evaluated for their immunogenicity and
potential to induce either humoral or cellular immunity.
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